F

ile this under “What were they thinking?”

For the second time this year, Pfizer has made substantial price hikes on some of its medicines, a move that disregards blistering criticism of the pharmaceutical industry over the cost of prescription drugs.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • geee,,,maybe its because all MEDICINE manufacturers are being sued by Adults who’s 30 year old ,”babies,”choose to use medicines like idiots,,,,,,maryw

  • If one wants to ‘observe’ that ‘Big Pharma’ is … uh, ‘s______g’ the customers, then using price increases on ‘the little blue pill’ is a fine point of emphasis.

  • New normal when one cannot create and develop new drugs for masses or expensive drugs for limited patients. Revenue has to go up to look good.

    • Shall we call this a ‘side effect’ of the Viagra patent extension to March 2020?

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy